anti-MUC1 CAR-T cells

BIOLOGICAL2 trials

Sponsors

PersonGen BioTherapeutics (Suzhou) Co., Ltd., The First Affiliated Hospital of Guangdong Pharmaceutical University

Conditions

Advanced Esophageal CancerColorectal CarcinomaGastric CarcinomaMalignant Glioma of Brain

Phase 1

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Colorectal Carcinoma, Gastric Carcinoma, Malignant Glioma of Brain

Start: 2015-11-30End: 2018-11-30Target: 20Updated: 2016-12-06

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

The First Affiliated Hospital of Guangdong Pharmaceutical UniversityAdvanced Esophageal Cancer

Start: 2018-09-28End: 2021-09-28Target: 20Updated: 2018-10-16

Related Papers

Phase I clinical trial using a unique immunotherapeutic combination of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of patients with advanced esophageal cancer.

Journal of Clinical Oncology2023-06-017 citations